Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB-200646A is an orally active, selective antagonist of 5-HT2B/2C over 5-HT2A receptor with pKi of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646A exerts anxiolytic and electrophysiological properties in vivo.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 35.00 | |
1 mL * 10 mM (in DMSO) | 5 days | $ 76.00 |
Description | SB-200646A is an orally active, selective antagonist of 5-HT2B/2C over 5-HT2A receptor with pKi of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646A exerts anxiolytic and electrophysiological properties in vivo. |
In vitro | SB200646A (4 μM) eliminates the increase in miniature inhibitory postsynaptic current (mIPSC) frequency induced by ethanol, without affecting the basal mIPSC frequency. |
In vivo | SB-200646A (20 mg/kg; intravenous injection; daily; for 21 days; male albino Sprague-Dawley rats) treatment significantly decreases the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons. The i.v. administration of 4-16 mg/kg of SB-200646A significantly increases the firing rate and % events as bursts in spontaneously active VTA dopaminergic neurons and significantly increases the % events as burst in substantia nigra pars compacta (SNC) dopaminergic neurons[1]. |
Molecular Weight | 302.76 |
Formula | C15H15ClN4O |
CAS No. | 143797-62-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 225 mg/mL (743.2 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SB-200646A 143797-62-0 GPCR/G Protein Neuroscience 5-HT Receptor SB 200646A SB200646A inhibitor inhibit